Mazor Robotics Ltd – (NASDAQ:MZOR) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $45.67.
MZOR has been the subject of several analyst reports. BidaskClub lowered shares of Mazor Robotics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Zacks Investment Research lowered shares of Mazor Robotics from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. Barclays reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Mazor Robotics in a research report on Wednesday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Tuesday, November 7th. Finally, Ladenburg Thalmann Financial Services set a $67.00 price objective on shares of Mazor Robotics and gave the company a “buy” rating in a research report on Monday, October 30th.
Institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc raised its position in Mazor Robotics by 87.2% during the 4th quarter. IFP Advisors Inc now owns 2,275 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 1,060 shares during the last quarter. Advisor Group Inc. raised its position in Mazor Robotics by 365.8% during the 3rd quarter. Advisor Group Inc. now owns 2,795 shares of the medical instruments supplier’s stock worth $138,000 after buying an additional 2,195 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in Mazor Robotics by 107.3% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,811 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 1,973 shares during the last quarter. Quantbot Technologies LP purchased a new position in Mazor Robotics during the 2nd quarter worth approximately $135,000. Finally, Halbert Hargrove Russell LLC purchased a new position in Mazor Robotics during the 3rd quarter worth approximately $214,000. 26.37% of the stock is owned by hedge funds and other institutional investors.
Mazor Robotics (NASDAQ:MZOR) traded down $0.04 during mid-day trading on Friday, hitting $64.68. 202,007 shares of the company’s stock traded hands, compared to its average volume of 536,271. The stock has a market capitalization of $1,770.00, a price-to-earnings ratio of -91.20 and a beta of 1.16. Mazor Robotics has a 1-year low of $21.21 and a 1-year high of $69.37.
Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.19. Mazor Robotics had a negative net margin of 28.80% and a negative return on equity of 22.68%. sell-side analysts forecast that Mazor Robotics will post -0.72 earnings per share for the current fiscal year.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.